

Qiagen expands digital PCR portfolio with new lentivirus solutions

01 May 2025 | News

To help accelerate the development of safe and effective biotherapeutics



Qiagen has announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalised form of cancer immunotherapy.

This expanded offering supports standardised, high-precision quality control (QC) workflows and strengthens the position of QIAGEN as a trusted partner for quality control, supporting biotech and biopharma companies, Contract Development and Manufacturing Organisations (CDMO) and therapy developers in CGT manufacturing.

The **QIAcuity RCL Quant Kit** detects replication-competent lentivirus (RCL), a key safety concern in lentiviral vector production. The kit uses clear step-by-step protocols to find even small amounts of RCL, helping therapy developers meet regulations and keep treatments safe.

The new **QIAcuity CGT dPCR assays**, including eight different wet-lab verified lentiviral targets, are designed for viral vector genome titration (measuring the amount of therapeutic virus particles) and vector copy number (VCN) determination (counting how many copies of a gene are inserted into each cell).

The new **CGT Lentivirus Lysis Kit and protocol**, combined with QIAcuity CGT dPCR assays, enables vector genome titer quantification with fewer hands-on steps, enhanced accuracy and repeatability.